147 related articles for article (PubMed ID: 12011258)
1. Melanoma growth stimulatory activity in primary malignant melanoma: prognostic significance.
Middleman BR; Friedman M; Lawson DH; DeRose PB; Cohen C
Mod Pathol; 2002 May; 15(5):532-7. PubMed ID: 12011258
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the role of melanoma growth stimulatory activity (MGSA) in the growth of normal melanocytes, nevocytes, and malignant melanocytes.
Bordoni R; Fine R; Murray D; Richmond A
J Cell Biochem; 1990 Dec; 44(4):207-19. PubMed ID: 2095366
[TBL] [Abstract][Full Text] [Related]
3. Melanoma growth stimulatory activity: isolation from human melanoma tumors and characterization of tissue distribution.
Richmond A; Thomas HG
J Cell Biochem; 1988 Feb; 36(2):185-98. PubMed ID: 3356754
[TBL] [Abstract][Full Text] [Related]
4. Autocrine and paracrine roles for growth factors in melanoma.
Shih IM; Herlyn M
In Vivo; 1994; 8(1):113-23. PubMed ID: 7519892
[TBL] [Abstract][Full Text] [Related]
5. Maspin expression, angiogenesis, prognostic parameters, and outcome in malignant melanoma.
Chua R; Setzer S; Govindarajan B; Sexton D; Cohen C; Arbiser JL
J Am Acad Dermatol; 2009 May; 60(5):758-66. PubMed ID: 19389518
[TBL] [Abstract][Full Text] [Related]
6. Growth factor modulation of melanoma growth stimulatory activity mRNA expression in human malignant melanoma cells correlates with cell growth.
Bordoni R; Thomas G; Richmond A
J Cell Biochem; 1989 Apr; 39(4):421-8. PubMed ID: 2722970
[TBL] [Abstract][Full Text] [Related]
7. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
8. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression.
Montone KT; van Belle P; Elenitsas R; Elder DE
Mod Pathol; 1997 Sep; 10(9):939-44. PubMed ID: 9310959
[TBL] [Abstract][Full Text] [Related]
9. Enhanced tumor-forming capacity for immortalized melanocytes expressing melanoma growth stimulatory activity/growth-regulated cytokine beta and gamma proteins.
Owen JD; Strieter R; Burdick M; Haghnegahdar H; Nanney L; Shattuck-Brandt R; Richmond A
Int J Cancer; 1997 Sep; 73(1):94-103. PubMed ID: 9334815
[TBL] [Abstract][Full Text] [Related]
10. Loss of EphB6 expression in metastatic melanoma.
Hafner C; Bataille F; Meyer S; Becker B; Roesch A; Landthaler M; Vogt T
Int J Oncol; 2003 Dec; 23(6):1553-9. PubMed ID: 14612926
[TBL] [Abstract][Full Text] [Related]
11. Cell-binding and growth-stimulating activities of the C-terminal part of human MGSA/Gro alpha.
Roby P; Page M
Biochem Biophys Res Commun; 1995 Jan; 206(2):792-8. PubMed ID: 7826402
[TBL] [Abstract][Full Text] [Related]
12. Apolipoprotein D expression in cutaneous malignant melanoma.
Miranda E; Vizoso F; Martín A; Quintela I; Corte MD; Seguí ME; Ordiz I; Merino AM
J Surg Oncol; 2003 Jun; 83(2):99-105. PubMed ID: 12772203
[TBL] [Abstract][Full Text] [Related]
13. Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.
Vitoux D; Mourah S; Kerob D; Verola O; Basset-Seguin N; Baccard M; Schartz N; Ollivaud L; Archimbaud A; Servant JM; Revol M; Toubert ME; Podgorniak MP; Plassa F; Porcher R; Lebbé C
Arch Dermatol; 2009 Oct; 145(10):1105-13. PubMed ID: 19841396
[TBL] [Abstract][Full Text] [Related]
14. Distributions of melanoma growth stimulatory activity of growth-regulated gene and the interleukin-8 receptor B in human wound repair.
Nanney LB; Mueller SG; Bueno R; Peiper SC; Richmond A
Am J Pathol; 1995 Nov; 147(5):1248-60. PubMed ID: 7485389
[TBL] [Abstract][Full Text] [Related]
15. The pathogenic role of growth factors in melanoma.
Richmond A
Semin Dermatol; 1991 Sep; 10(3):246-55. PubMed ID: 1931574
[TBL] [Abstract][Full Text] [Related]
16. Effects of MGSA/GRO alpha on melanocyte transformation.
Balentien E; Mufson BE; Shattuck RL; Derynck R; Richmond A
Oncogene; 1991 Jul; 6(7):1115-24. PubMed ID: 1861861
[TBL] [Abstract][Full Text] [Related]
17. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
18. Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma.
Massi D; Naldini A; Ardinghi C; Carraro F; Franchi A; Paglierani M; Tarantini F; Ketabchi S; Cirino G; Hollenberg MD; Geppetti P; Santucci M
Hum Pathol; 2005 Jun; 36(6):676-85. PubMed ID: 16021575
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
[TBL] [Abstract][Full Text] [Related]
20. A His19 to Ala mutant of melanoma growth-stimulating activity is a partial antagonist of the CXCR2 receptor.
Baly DL; Horuk R; Yansura DG; Simmons LC; Fairbrother WJ; Kotts C; Wirth CM; Gillece-Castro BL; Toy K; Hesselgesser J; Allison DE
J Immunol; 1998 Nov; 161(9):4944-9. PubMed ID: 9794430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
